Investigations on Plasma Activity of Low Molecular Weight Heparin After Intravenous and Oral Administrations

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 1989 Aug 1

PMID 2550047

Citations 6

Authors

M Dryjski

D E SCHNEIDER

P Mojaverian

B S Kuo

T D Bjornsson

Affiliations

Soon will be listed here.

Abstract

This study investigated the absorption of low molecular weight heparin (LMWH) after oral administration in man. Six healthy subjects received 5,000 anti-Xa units of LMWH (Kabi 2165) by both i.v. and oral administration. The oral formulations were prepared in pH 4.0 and pH 7.0 buffered solutions. Multiple blood samples were collected after each dose for measurements of anti-Xa, anti-IIa and APTT plasma heparin activities. Pharmacokinetic parameters based on the anti-Xa activity measurements after the i.v. dose were as follows (mean +/- s.d.): t1/2, 1.82 +/- 0.23 h; V, 4.34 +/- 0.651; and CL, 28.0 +/- 6.2 ml min-1. Half-life values based on the anti-IIa and APTT activities were 1.63 +/- 0.43 and 1.09 +/- 0.51 h, respectively. Considerable prolongations in APTT were observed, with APTT at 30 min averaging 55.7 +/- 4.1 s (1.84 +/- 0.27 times baseline values). After oral administration, no measurable plasma heparin activities were observed with either LMWH preparation. The results of this investigation indicate that LMWH does not have detectable plasma activity after oral administration, and that after i.v. administration it has significant anti-IIa and APTT activities in addition to its anti-Xa activity.

Citing Articles

Movement of heparins across rat gastric mucosa is dependent on molecular weight and pH.

Moazed B, Hiebert L Pharm Res. 2008; 26(1):189-95.

PMID: 18937058 DOI: 10.1007/s11095-008-9751-8.

Enhanced antithrombotic effects of unfractionated heparin in rats after repeated oral doses and its relationship to endothelial heparin concentration.

Hiebert L, Ping T, Wice S Br J Pharmacol. 2008; 153(6):1177-84.

PMID: 18264127 PMC: 2275434. DOI: 10.1038/bjp.2008.14.

The quest for non-invasive delivery of bioactive macromolecules: a focus on heparins.

Motlekar N, Youan B J Control Release. 2006; 113(2):91-101.

PMID: 16777255 PMC: 1539865. DOI: 10.1016/j.jconrel.2006.04.008.

Excretion of low molecular weight heparin in human milk.

Richter C, Sitzmann J, Lang P, Weitzel H, Huch A, Huch R Br J Clin Pharmacol. 2001; 52(6):708-10.

PMID: 11736885 PMC: 2014571. DOI: 10.1046/j.0306-5251.2001.01517.x.

Dalteparin: an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease.

Dunn C, Jarvis B Drugs. 2000; 60(1):203-37.

PMID: 10929935 DOI: 10.2165/00003495-200060010-00010.

References

WINDSOR E, CRONHEIM G . Gastro-intestinal absorption of heparin and synthetic heparinoids. Nature. 1961; 190:263-4. DOI: 10.1038/190263a0. View

Larsen A, Lund D, Langer R, Folkman J . Oral heparin results in the appearance of heparin fragments in the plasma of rats. Proc Natl Acad Sci U S A. 1986; 83(9):2964-8. PMC: 323427. DOI: 10.1073/pnas.83.9.2964. View

Murray G, BEST C . THE USE OF HEPARIN IN THROMBOSIS. Ann Surg. 1938; 108(2):163-77. PMC: 1386890. DOI: 10.1097/00000658-193808000-00002. View

KOH T, BHARUCHA K . Intestinal absorption of stable heparinic acid complexes. J Lab Clin Med. 1972; 80(1):47-55. View

Doutremepuich C, Masse A, OCA C, Maury M, Gestreau J, Toulemonde F . [Duodenal absorption of a low molecular weight heparin in rabbits]. Pathol Biol (Paris). 1984; 32(1):45-8. View

Bjornsson T, Wolfram K, Kitchell B . Heparin kinetics determined by three assay methods. Clin Pharmacol Ther. 1982; 31(1):104-13. DOI: 10.1038/clpt.1982.16. View

LOOMIS T . Absorption of heparin from the intestine. Proc Soc Exp Biol Med. 1959; 101(3):447-9. DOI: 10.3181/00379727-101-24974. View

Bratt G, Tornebohm E, WIDLUND L, Lockner D . Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers. Thromb Res. 1986; 42(5):613-20. DOI: 10.1016/0049-3848(86)90340-3. View

Andersson L, Barrowcliffe T, Holmer E, Johnson E, Sims G . Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin iii and by gel filtration. Thromb Res. 1976; 9(6):575-83. DOI: 10.1016/0049-3848(76)90105-5. View

10.

Bratt G, Tornebohm E, Lockner D, Bergstrom K . A human pharmacological study comparing conventional heparin and a low molecular weight heparin fragment. Thromb Haemost. 1985; 53(2):208-11. View

11.

Larsen M, Abildgaard U, Teien A, Gjesdal K . Assay of plasma heparin using thrombin and the chromogenic substrate H-D-Phe-Pip-Arg-pNA (S-2238). Thromb Res. 1978; 13(2):285-8. DOI: 10.1016/0049-3848(78)90016-6. View

12.

Barzu T, Molho P, Tobelem G, Petitou M, Caen J . Binding of heparin and low molecular weight heparin fragments to human vascular endothelial cells in culture. Nouv Rev Fr Hematol (1978). 1984; 26(4):243-7. View

13.

Bjornsson T, Wolfram K . Intersubject variability in the anticoagulant response to heparin in vitro. Eur J Clin Pharmacol. 1982; 21(6):491-7. DOI: 10.1007/BF00542044. View

14.

Teien A, Lie M, Abildgaard U . Assay of heparin in plasma using a chromogenic substrate for activated factor X. Thromb Res. 1976; 8(3):413-6. DOI: 10.1016/0049-3848(76)90034-7. View

15.

Sue T, JAQUES L, Yuen E . Effects of acidity, cations and alcoholic fractionation on absorption of heparin from gastrointestinal tract. Can J Physiol Pharmacol. 1976; 54(4):613-7. DOI: 10.1139/y76-084. View

16.

Engel R, RIGGI S . Intestinal absorption of heparin facilitated by sulfated or sulfonated surfactants. J Pharm Sci. 1969; 58(6):706-9. DOI: 10.1002/jps.2600580612. View

17.

Holmer E, Kurachi K, SODERSTROM G . The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin. Biochem J. 1981; 193(2):395-400. PMC: 1162618. DOI: 10.1042/bj1930395. View